HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer

AbstractIntroduction This study was to investigate whether the expression of a disintegrin and metalloproteinase-9 (ADAM9) is correlated with the expression of hepatoma-derived growth factor (HDGF) in surgically resected non-small cell lung cancer (NSCLC), to evaluate the significance of HDGF and ADAM9 as novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for postoperative adjuvant chemotherapy in surgically resected stage I NSCLC, to provide essential consistence proof to the possible novel pathway of HDGF–ADAM9 pathway.MethodsSixty-three cases of resected stage I NSCLC with mediastinal N2 lymph node dissection were immunohistochemically analyzed for HDGF and ADAM9 protein expression. Multivariate analysis and survival analysis were conducted.ResultsHDGF and ADAM9 were observed highly expressed in NSCLC compared with normal control lung tissues (P < 0.05). HDGF high expression cases showed significantly lower survival rate (55.6 vs. 84.7 %, P = 0.009). HDGF high expression was an independent factor of shortened survival time in resected stage I NSCLC (P = 0.015). ADAM9 high expression cases showed significantly lower survival rate (56.9 vs. 88.7 %, P = 0.015). ADAM9 high expression was an independent factor of shortened survival time in resected stage I NSCLC (P = 0.021). Pearson’s correlation analysis revealed that ADAM9 expression was correlated positively and significantly with HDGF expression in 63 cases of stage I NSCLC (r = 0.547, P = 0.000).ConclusionThese results clearly demonstrate that ADAM9 high expression is correlated positively and significantly with HDGF high expression, which provides essential evidence for the novel HDGF–ADAM9 pathway, through which HDGF promotes invasion and metastasis of NSCLC cells; HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers, which might become useful predictive biomarkers for the selection of postoperative adjuvant chemotherapy treatment in surgically resected stage I NSCLC.

[1]  C. Pilarsky,et al.  ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma , 2004, British Journal of Cancer.

[2]  H. Saka,et al.  Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Donglei Liu,et al.  MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  W. Fang,et al.  Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer , 2010, Diagnostic pathology.

[5]  M. Monden,et al.  Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer , 2006, Clinical Cancer Research.

[6]  G. Kristiansen,et al.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression , 2008, BMC Cancer.

[7]  Hideji Nakamura,et al.  Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. , 2000, The Journal of clinical investigation.

[8]  My T. Thai,et al.  Bound and exact methods for assessing link vulnerability in complex networks , 2014, J. Comb. Optim..

[9]  A. He,et al.  HDGF在手术切除非小细胞肺癌中的异常表达及其在预测预后中的意义 , 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[10]  A. Zubel,et al.  Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. , 2009, Gynecologic oncology.

[11]  Y. Doki,et al.  Expression of Hepatoma-Derived Growth Factor Is Correlated with Lymph Node Metastasis and Prognosis of Gastric Carcinoma , 2006, Clinical Cancer Research.

[12]  L. Mao,et al.  Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. , 2006, Cancer research.

[13]  John D. Minna,et al.  Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Andrea Tannapfel,et al.  Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays , 2003, The Journal of pathology.

[15]  A. Kraus,et al.  Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. , 2001, European journal of cancer.

[16]  T. le Chevalier,et al.  Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jean-Yves Douillard,et al.  Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hideji Nakamura,et al.  Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. , 2005, Oncology reports.

[19]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[20]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[21]  J. Roth,et al.  Survival in early-stage non-small cell lung cancer. , 1995, The Annals of thoracic surgery.

[22]  C. Pilarsky,et al.  ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. , 2008, European urology.

[23]  PhD Yuichiro Doki MD,et al.  Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma , 2007, Annals of Surgical Oncology.

[24]  M. Duffy,et al.  Expression of ADAM‐9 mRNA and protein in human breast cancer , 2003, International journal of cancer.

[25]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[27]  A. Tucker,et al.  Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[28]  A. Roessner,et al.  The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. , 2005, International journal of oncology.

[29]  N. Chen,et al.  High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer , 2013, Oncology letters.

[30]  F. Khuri,et al.  Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.